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ABSTRACT 
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. Its clinical 
course is typically indolent; 
however, based on a series of pathobiological, clinical, genetic, and phenotypic 
parameters, patient survival varies from 
less than 5 to more than 20 years. In this paper, we show for the first time that the expression 
of the interferon-inducible 
DNA sensor IFI16, a member of the PYHIN protein family involved in proliferation inhibition 
and apoptosis regulation, 
is associated with the clinical outcome in CLL. We studied 99 CLLs cases by 
immunohistochemistry and 10 
CLLs cases by gene expression profiling. We found quite variable degrees of IFI16 
expression among CLLs cases. 
Noteworthy, we observed that a reduced IFI16 expression was associated with a very poor 
survival, but only in cases 
with ZAP70/CD38 expression. Furthermore, we found that IFI16 expression was 
associated with a specific gene expression 
signature. As IFI16 can be easily detected by immunohistochemistry or flow cytometry, it 
may become a part of 
phenotypic screening in CLL patients if its prognostic role is confirmed in independent 
series. 
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INTRODUCTION 
Chronic lymphocytic leukemia (CLL) is the most 
common leukemia type in adults in Western countries 
(1). Rarely, the disease lacks the typical spread 
of leukemia, presenting with evident nodal localization, 
and it is classified as a small lymphocytic lymphoma 
(SLL) (1). Clinically, CLL is indolent, with 
a median overall survival (OS) exceeding 15 years 
(2). However, based on clinical (e.g., stage and 
doubling time), phenotypic, and genetic features, it can be completely indolent or quite 
aggressive. 
Specifically, the overall expression of CD38, 
ZAP70, LAIR1, and CD49d biomarkers, though 
not univocally, indicates an activation of the leukemic 
B cell and it is related to a worse outcome (3– 
5). In addition, immunohistological analyses have 
demonstrated that the identification of abundant 
proliferating centers is associated to a worse behavior 
(6). Similarly, the absence of somatic hypermutations 
in the immunoglobulin heavy chain genes (IGH) or recognition of specific stereotypes 
indicates an aggressive disease (1, 3, 4). Genetically, 
few chromosomal imbalances that can be detected 
by a FISH analysis, including del(17p), del(11q), 
+12, and del(13q), are associated with a more or 
less aggressive clinical behavior (7). Recently, nextgeneration 
sequencing has allowed the identification 
of a series of lesions affecting TP53, BIRC3, 
SF3B1, MYD88, and NOTCH1 that significantly 
influence patient prognosis (8). Expression levels of 
specific miRNA have also been associated with 
clinical outcome, although these results have occasionally 
been controversial (9–11). Notably, the 
integration of FISH and molecular data has been 
clinically meaningful in defining subgroups with 
significant differences in overall survival (8). However, 
despite such evidence, most patients are not 
currently evaluated at diagnosis with a complete 
molecular and genetic make-up. Patients sometimes 
undergo FISH and extensive gene sequencing at 
disease progression if aged below 60–65 years old 
(12). Conversely, most patients are studied at diagnosis 
using flow cytometry (CD38/ZAP70) and 
IGH@ sequencing only. 
Recently, our group indicated that IFI16 is regulated 
during B-cell differentiation (13). Its levels are 
particularly elevated in memory B cells. 
In addition, IFI16 expression has been shown to 
have an intriguing relationship with some major 
transcription factors, such as BCL6, NF-jB, STAT3, 
and STAT5, involved in central processes of the 
B-cell biology (13,14). IFI16 is a member of the 
PYHIN family of proteins and is involved in 
immune response, cell viability, differentiation, proliferation, 
senescence, and restriction of virus replication 
(15–17). Specifically, IFI16 plays a central role 
in innate immunity, especially during viral infections. 
IFI16 is a DNA sensor that regulates IFN expression 
and inflammasome activation by negatively 
affecting the viability of infected cells (18–21). In 
addition to its role in innate immunity, several 
observations have indicated that IFI16 is a transcriptional 
regulator through heterodimerization with 
other transcription factors, which suggest different 
roles of IFI16 depending on the cell type (15). In different 
cell models, IFI16 has been demonstrated to 
either activate apoptosis or inhibit proliferation by 
interacting with other cell cycle and survival gatekeepers 
including p53 and Rb, and in addition, it is 
able to restrict virus replication (21–25). This antitumor 
activity is not absolute but is well-described 
in different cell models (16, 26, 27). Together, these 
studies suggest that an alteration in IFI16 activity 
and/or expression could play an important role in Bcell 
proliferation. Hence, we investigated IFI16 
expression in CLL to uncover its potential pathogenetic/ 
prognostic role in this study.  
 
MATERIALS AND METHODS 
Case series 
A total of 99 lymph node samples obtained from CLL 
patients diagnosed according to NCI criteria were 
included in this study. Lymph node biopsies in these 
patients were performed in the presence of progressive disease 
requiring treatment, with adenopathies ≥3 cm (6). 
Patients were referred to the Hematopathology Unit of S. 
Orsola-Malpighi Hospital, Bologna University, Bologna, 
Italy, for a histological diagnosis between 2002 and 2008. 
The only selection criterion was the availability of a sufficient 
amount of formalin-fixed paraffin-embedded (FFPE) 
tissue. The main clinical-pathological features of these 
patients are summarized in Table 1. The cases showing 
confluent proliferation centers (PCs) were classified as 
“PC-rich”. Additionally, 10 CLL cases were studied, previously 
generated by our group (28). 
 
Immunohistochemistry and fluorescence in situ 
hybridization (FISH) on tissue microarrays 
A Giemsa-stained slide was prepared from each paraffin 
block containing representative tumor regions marked on 
every slide. Tissue cylinders with a diameter of 1.0 mm 
were punched from the marked areas on each block and 
placed in a recipient paraffin block using a precision 
instrument as previously described (6, 10). Punches were 
performed on areas of monotonous small lymphocytes 
and on areas with proliferating centers, when present. 
Tissue microarrays (TMAs) were prepared for immunohistochemistry 
and fluorescence in situ hybridization FISH 
studies. by immunohistochemistry (IHC) on TMAs from the 99 
cases (in duplicate cores). From each recipient block, 1.5- 
lm-thick sections were cut and tested with anti-ZAP70 
(Upstate, Millipore, Billerica, MA, USA, clone 2F3.2: 
dilution 1:80; (29,30)), anti-CD38 (Novocastra, Menarini 
Diagnostics, Grassina, Italy, clone SPC32: dilution 1:80), 
and anti-IFI16 mouse monoclonal antibodies (Sigma, 
Milan Italy, dilution 1:100). Briefly, paraffin-embedded 
sections were dewaxed and submitted to antigen retrieval 
by heating in Dako PTLink (DakoCytomation, Glostrup, 
Denmark; code PT100/PT101) in an EnVision Flex Target 
Retrieval Solution High pH (DakoCytomation; code 
K8004) at 92 °C for 5 min. Sections were incubated at 
room temperature with fetal calf serum (10 min) and then 
with the specific primary antibody (for 30 min). Each 
evaluation was performed by at least two expert 
hematopathologists blinded to the study. Scores were compared 
and consensus agreement was reached at the microscope 
in all cases. 
Immunohistochemistry stainings were scored based on 
the percentage of positive neoplastic cells (visual count 
performed by two hematopathologists) as follows: 0 = no 
positive cells; 1 = 1–20%; 2 = 21–40%; 3 = 41–60%; 4 = 
61–80%; and 5 = 81–100%. Micrographs were obtained 
using an Olympus BX61 microscope equipped with an 
Olympus DP-70 digital camera, and image acquisition, 
evaluation, and color balance were performed using 
Cell^F software. The probes used in fluorescence in situ 
hybridization FISH study, as well as preparation of the 
slides, hybridization, and cut-off for positivity FISH signal 
screening are detailed in our previous report (6). 
 
Gene expression analyses 
We analyzed the previously generated gene expression profile 
(GEP) data reported by our group on 10 CLL cases 
(28) not included within the 99 studied by IHC. All data 
were obtained using Affymetrix HG-U133 2.0 plus 
microarrays (Affymetrix, Inc. http://www.affymetrix.c 
om/support/index.affx) available at http://www.ncbi.nlm. 
nih.gov/projects/geo/(28). For further technical details and 
patient characteristics, see references (28). 
We focused our analysis on IFI16 expression. We identified 
IFI16 expression using three different probe sets 
(206332_s_at; 208966_x_at; and 208965_s_at) in the HGU133 
datasets and one (1456_s_at) in HG-U95. The mean 
values from the three probes were used to analyze HGU133 
data. GEP analyses were performed using Gene- 
Spring GX 12.0 Software (Agilent Technologies, Santa 
Clara, CA, USA; (28, 29, 31, 32)). 
 
Statistical analysis 
Statistical analyses were performed using IBM SPSS 
Statistics 20.0. ANOVA and unpaired T-tests were used. 
When a sample size was less than 10 cases in at least one 
group, a non-parametric (Mann–Whitney) test was used 
to analyze the GEP data to compare IFI16 expression in 
different subgroups (11). The limit of significance for all 
analyses was defined as p < 0.05. Two-sided tests were 
used in all calculations. Possible relationships between the 
immunohistochemical expression of IFI16 and other clinico- 
pathological parameters were evaluated using a T-test or chi-square test for continuous 
and non-continuous variables, 
respectively (6, 10). The univariate association 
between individual clinical features and DSS was determined 
with the log-rank or Wilcoxon test, when appropriate. 
A multivariate analysis using the Cox proportional 
hazards regression model was performed to compare the 
factors studied in univariate analysis. The limit of significance 
for all analyses was defined as p < 0.05; two-sided 
tests were used in all calculations. 
 
RESULTS 
IFI16 is variably expressed in B-CLL 
We tested IFI16 protein expression in the 99 lymph 
nodes from patients affected by CLL/SLL and the 
5 lymph nodes characterized by florid reactive 
hyperplasia. We observed IFI16 expression in all 
the CLL and non-neoplastic hyperplastic samples. 
As expected, the latter had intense staining mainly 
localized in the mantle zone. This confirmed our 
data from previous studies (13). In the CLL cases, 
nuclear staining was detected in 10–100% of the 
cells. The overall staining was intense. Only a few 
cases had a weaker reaction that was not related to 
other features, including the percentage of positive 
cells. In cases with a prominent proliferating center 
(PC), we observed a gradient of IFI16 expression, 
which was higher within the PC (Fig. 1). However, 
no significant correlation between the abundance of 
PC and IFI16 expression was recorded. The expression 
pattern (mainly nuclear) corresponded to the 
one, previously reported in human lymphocytes 
(13). Overall, TMAs resulted adequate for a proper 
evaluation and full section re-evaluation was not 
needed. 
 
IFI16 lower protein levels are associated with 
unfavorable outcome 
We investigated whether IFI16 protein expression 
was correlated with any specific clinic-pathological 
parameter. No significant correlation was observed, 
with the exception of del(13q) that was associated 
with a significantly lower IFI16 expression 
(Table 2; Fig. 2). Despite the significance at T-test, 
as IFI16 protein expression values in terms of percentage 
of positive cells at immunohistochemistry 
(IHC) appeared quite overlapping in the two 
groups (with and without del13p, respectively) 
(Fig. 2), we also tested by chi-square whether cases 
without del13p had more frequently higher (i.e., 
more than 50% of positive cells at IHC) IFI16 
expression. Indeed, also this correlation turned out 
to be statistically significant (p = 0.02). 
We then tested the possible impact of the main 
clinic-pathological parameters on the clinical outcome. 
Following the univariate analysis, only the presence of del(13q) and del(17p) and a low 
IFI16 
expression correlated with an inferior OS (Table 3; 
Fig. 3). 
When the CLLs were divided into two groups, 
based on IFI16 expression (i.e., scored at immunohistochemistry 
0–2 vs 3–5, IFI16low vs IFI16high, 
respectively), the group with lower IFI16 expression 
was characterized by a significantly shorter mean 
OS (55.6 vs 95.4 months, 95% confidence interval 
78.9–111.7 vs 27.7–83.6). A median OS, in the 
IFI16high group was not reached. However, the median OS in the IFI16low group was 46 
months 
(Fig. 3). By contrast, in the multivariate analysis, 
only the presence of genetic lesions affecting chromosomes 
14p and 17p were associated with a 
shorter OS. 
Finally, because IFI16 expression can correlate 
with physiological lymphocyte activation, we investigated 
whether IFI16 expression might be related 
to CLL cell activation, as well. For this purpose, 
each CLL case was considered “activated” if either 
CD38 or ZAP70 was expressed. Based on this criterion, 
we divided the cases into four groups according 
to IFI16 and ZAP70/CD38 protein expression 
(Fig. 3; Table 4) to test a possible prognostic 
impact. The four groups were, in fact, significantly 
different in OS (p = 0.004). Specifically, patients 
with high ZAP70/CD38 but low IFI16 expression (group 3) had worse outcomes (median 
6.5 months, 
95% confidence interval 4.4–8.6 months). Those 
with higher IFI16, both with lower (group 2) or 
negative (group 1) ZAP70/CD38 expression had the 
best outcomes (median not reached; mean 86.7 and 
97.7 months, respectively; 95% confidence interval 
69–104.4 and 76.3–119.2 months, respectively). The 
CLLs characterized by IFI16 low and no ZAP70/ 
CD38 expression had an intermediate clinical profile 
(median survival 46 months; 95% confidence 
interval 0–93.4 months; Fig. 5). 
 
IFI16 low expression is associated with a peculiar 
gene expression profile 
To better understand the pathobiological significance 
of IFI16 expression in CLL, we compared 
the GEP of CLLs with higher (>50% percentile) 
and lower (< 50% percentile) IFI16 gene expression. 
In a supervised analysis (T-test, p < 0.05), we 
identified 271 probe sets, which corresponds to 226 
unique genes differentially expressed between the 
two groups (Fig. 4; raw data available upon 
request). Specifically, 163 were up-regulated and 63 
were down-regulated in the more aggressive group 
(i.e., with lower IFI16 expression). 
In the IFI16low CLL group, we observed up-regulation 
of JUN and JUNB, two transcription factors 
often up-regulated in malignant phenotypes, 
and CXCR4, a chemokine receptor that regulates 
bone marrow adhesion of neoplastic elements which 
possibly contributes to chemoresistance in CLL 
(33). Down-regulation of IKZF3, a tumor suppressor 
previously found to be altered in lymphoid leukemias 
and other cancers (34) was also observed. When we investigated pathways and cellular 
programs 
possibly overrepresented among the differentially 
expressed genes, we found several biological 
processes and cancer-related molecular signatures/ 
pathways (Fig. 4; Tables 5-6). We noted a significant 
enrichment in the expression of genes involved 
in DNA repair, RNA processing and transcription, 
and response to stress and DNA damage. We also 
found that the expression of genes usually involved 
in the EGFR, VEGF, MTOR, and PDGFR signaling, 
and genes, associated with RB1, RBL2, and 
KRAS deregulation, were enriched. 
 
DISCUSSION 
Chronic lymphocytic leukemia is typically indolent. 
However, patient survival varies from less than 5 to 
more than 20 years depending on the biological characteristics 
of the disease (8). Accordingly, treatments 
have to be tailored based on patients’ specific features. 
These treatments range from watch-and-wait to 
chemo-immunotherapy, signaling inhibitors, and stem 
cell transplantation (35–37). The main biological 
parameters that influence CLL aggressiveness are 
genetic (such as immunoglobulin somatic hypermutations/ 
ISHM or somatic lesions detectable by FISH or 
DNA sequencing) and functional (usually detected by 
flow cytometry and indicative of cellular activation). 
Although a complete genetic characterization is probably 
the optimal approach to CLL prognostication, 
for practical reasons, mainly timing and cost, only 
phenotypic characterization is used in elderly people. 
Genetic characterization is used more often in patients 
presenting with symptoms at a younger age. Recently, the importance of the phenotypic 
profiling has been 
highlighted by the identification of progranulin, a 
molecule overexpressed in CD38+/ZAP70+ cases with 
negative prognostic relevance (38). 
In this study, we explored the possible relation 
between IFI16 expression and prognosis. IFI16 is 
an interferon-related molecule that regulates cellular 
activation, signaling, and eventually, cell proliferation 
and apoptosis (15–17, 21, 39, 40). In B cells, 
IFI16 expression consistently parallels maturation 
and differentiation of the germinal center toward 
memory and plasma cells (13, 41). For the first 
time, we found that IFI16 expression might be 
related to CLL clinical outcomes. Specifically, reduced IFI16 corresponded to a worse 
clinical scenario 
when molecules such as ZAP70 and CD38 
were expressed (median survival 6.5 months). As 
IFI16 expression is retained in the normal cellular 
counterparts of CLL (13), a reduced expression can 
be used as a pathological feature. Because of the known functions of IFI16, it is 
conceivable that the lack of IFI16, which is associated 
with a reduced antiproliferative effect, might 
be particularly severe in cells constitutively receiving 
an activation/proliferation signaling. Therefore, 
it should be noted that the prognostic role of 
ZAP70 and CD38 expression has not been confirmed. 
Based on the present results, we can assume 
that the balance between IFI16 expression and activation 
signaling (mediated by ZAP70/CD38) may represent a more reliable parameter. A 
maintained 
IFI16 expression is capable of at least partially 
compensating for the negative influence of ZAP70 
and CD38. 
The major limitation of this study is the lack of 
a comprehensive genetic characterization of the disease, 
including all novel markers, because DNA 
was not available for such studies. Certainly, the 
genetic background might affect IFI16 expression. 
Regardless, ISHM, TP53 mutations, and FISH 
could be performed as a good basic evaluation. On 
the other hand, testing the prognostic value of 
IFI16 in an independent, possibly prospective, series 
of cases is warranted. Furthermore, it should be 
noted that the distribution of cytogenetic aberrations 
was quite untypical. In particular, the incidence 
of del(13q) was lower, while, on the contrary, 
the incidence of del(17p) and especially, del(11q) 
and del(14q) were higher than expected. However, 
as previously discussed (6), the only selection bias 
was represented by the availability of tissue. 
Finally, to simplify pathological assessment and 
increase reproducibility of immunohistochemical 
assays, an automated digital analyses would be possibly 
applied. 
In conclusion, we identified IFI16 as a possible 
prognostic marker in CLL. It might be clinically 
useful, especially in patients receiving a phenotypic 
rather than complete molecular characterization for 
any reason. 
 
CONFLICT OF INTEREST 
The authors have no conflicting financial interests 
to declare. 
PPP and DG designed the study, performed analyses, and 
wrote the manuscript. CA, SR, MR, and MC performed 
IHC and FISH analyses. MCR, IB, GM, CT, ED, CS, 
and CP performed data analysis. OP collected surgical 
samples. AC was responsible for patient care and clinical 
data collection. SL and DZ contributed to conceiving the 
study and the paper drafting and writing. This work was 
supported by BolognAIL, AIRC, RFO (Prof. Piccaluga), 
FIRB Futura 2011 RBFR12D1CB (Prof. Piccaluga), and 
Fondi Dipartimentali (Gibellini). 
REFERENCES 
1. Muller-Hermelink HK, Montserrat E, Catovsky D, 
Campo E, Harris NL, Stein H. Chronic lymphocytic 
leukaemia/small lymphocytic lymphoma. In: Swerdlow 
SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein 
H, Thiele J, Vardiman , editors. WHO Classification 
of Tumours of Haematopoietic and Lymphoid Tissues. 
Lion: IARC, 2008:180–2. 
2. Sun C, Wiestner A. Prognosis and therapy of chronic 
lymphocytic leukemia and small lymphocytic lymphoma. 
Cancer Treat Res 2015;165:147–75. 
3. Bulian P, Shanafelt TD, Fegan C, Zucchetto A, Cro 
L, N€uckel H, et al. CD49d is the strongest flow 
cytometry-based predictor of overall survival in 
chronic lymphocytic leukemia. J Clin Oncol 2014;32: 
897–904. 
4. Dal Bo M, Tissino E, Benedetti D, Caldana C, Bomben 
R, Del Poeta G, et al. Microenvironmental interactions 
in chronic lymphocytic leukemia: the master 
role of CD49d. Semin Hematol 2014;51:168–76. 
5. Perbellini O, Falisi E, Giaretta I, Boscaro E, Novella 
E, Facco M, et al. Clinical significance of LAIR1 
(CD305) as assessed by flow cytometry in a prospective 
series of patients with chronic lymphocytic leukemia. 
Haematologica 2014;99:881–7. 
6. Ciccone M, Agostinelli C, Rigolin GM, Piccaluga PP, 
Cavazzini F, Righi S, et al. Proliferation centers in 
chronic lymphocytic leukemia: correlation with cytogenetic 
and clinicobiological features in consecutive 
patients analyzed on tissue microarrays. Leukemia 
2012;26:499–508. 
7. D€ohner H, Stilgenbauer S, Benner A, Leupolt E, 
Kr€ober A, Bullinger L, et al. Genomic aberrations 
and survival in chronic lymphocytic leukemia. N Engl 
J Med 2000;343:1910–6. 
8. Rossi D, Rasi S, Spina V, Bruscaggin A, Monti S, 
Ciardullo C, et al. Integrated mutational and cytogenetic 
analysis identifies new prognostic subgroups in 
chronic lymphocytic leukemia. Blood 2013;121:1403– 
12. 
9. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu 
M, Wojcik SE, et al. A MicroRNA signature 
associated with prognosis and progression in chronic 
lymphocytic leukemia. N Engl J Med 2005;353:1793– 
801. 
10. Rossi M, Fuligni F, Ciccone M, Agostinelli C, Righi 
S, Luciani M, et al. Hsa-miR-15a and Hsa-miR-16-1 
expression is not related to proliferation centers abundance 
and other prognostic factors in chronic lymphocytic 
leukemia. Biomed Res Int 2013;2013:715391. 
11. Cui B, Chen L, Zhang S, Mraz M, Fecteau JF, Yu J, 
et al. MicroRNA-155 influences B-cell receptor signaling 
and associates with aggressive disease in chronic 
lymphocytic leukemia. Blood 2014;124:546–54. 
12. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio 
F, Dighiero G, D€ohner H, et al. Guidelines for the 
diagnosis and treatment of chronic lymphocytic leukemia: 
a report from the International Workshop on 
Chronic Lymphocytic Leukemia updating the 
National Cancer Institute-Working Group 1996 guidelines. 
Blood 2008;111:5446–56. 
13. Piccaluga PP, Agostinelli C, Fuligni F, Righi S, Tripodo 
C, Re MC, et al. IFI16 expression is related to 
selected transcription factors during B-Cell differentiation. 
J Immunol Res 2015;2015:747645. 
14. Basso K, Saito M, Sumazin P, Margolin AA, Wang 
K, Lim WK, et al. Integrated biochemical and computational 
approach identifies BCL6 direct target genes 
controlling multiple pathways in normal germinal center 
B cells. Blood 2010;115:975–84. 
15. Ludlow LA, Johnstone RW, Clarke CJ. The HIN-200 
family: more than interferon-inducible genes? Exp Cell 
Res 2005;308:1–17. 16. Choubey D, Deka R, Ho S. Interferon-inducible 
IFI16 protein in human cancers and autoimmune diseases. 
Front Biosci 2008;13:598–608. 
17. Gariglio M, Mondini M, De Andrea M, Landolfo S. 
The multifaceted interferon-inducible p200 family proteins: 
from cell biology to human pathology. J Interferon 
Cytokine Res 2011;31:159–72. 
18. Unterholzner L, Keatin SE, Baran M, Horan KA, 
Jensen SB, Sharma S, et al. IFI16 is an innate immune 
sensor for intracellular DNA. Nat Immunol 2010; 
11:997–1004. 
19. Paludan SR, Bowie AG, Horan KA, Fitzgerald KA. 
Recognition of herpesviruses by the innate immune 
system. Nat Rev Immunol 2011;11:143–54. 
20. Monroe KM, Yang Z, Johnson JR, Geng X, Doitsh 
G, Krogan NJ, et al. IFI16 DNA sensor is required 
for death of lymphoid CD4 T cells abortively infected 
with HIV. Science 2014;343:428–32. 
21. Zhao H, Gonzalezgugel E, Cheng L, Richbourgh B, 
Nie L, Liu C. The roles of interferon-inducible p200 
family members IFI16 and p204 in innate immune 
responses, cell differentiation and proliferation. Genes 
Dis 2015;2:46–56. 
22. Kwak JC, Ongusaha PP, Ouchi T, Lee SW. IFI16 as 
a negative regulator in the regulation of p53 and p21 
(Waf1). J Biol Chem 2003;278:40899–904. 
23. Xin H, Curry J, Johnstone RW, Nickoloff BJ, Choubey 
D. Role of IFI 16, a member of the interferoninducible 
p200-protein family, in prostate epithelial 
cellular senescence. Oncogene 2003;22:4831–40. 
24. Fujiuchi N, Aglipay JA, Ohtsuka T, Maehara N, 
Sahin F, Su GH, et al. Requirement of IFI16 for the 
maximal activation of p53 induced by ionizing radiation. 
J Biol Chem 2004;279:20339–44. 
25. Song LL, Alimirah F, Panchanathan R, Xin H, Choubey 
D. Expression of an IFN-inducible cellular senescence 
gene, IFI16, is up-regulated by p53. Mol Cancer 
Res 2008;6:1732–41. 
26. Zhang Y, Howell RD, Alfonso TD, Yu J, Kong L, 
Wittig JC, et al. IFI16 inhibits tumorigenicity and cell 
proliferation of bone and cartilage tumor cells. Front 
Biosci 2007;12:4855–63. 
27. Mazibrada J, De Andrea M, Ritt_a M, Borgogna C, 
Dell’Eva R, Pfeffer U, et al. In vivo growth inhibition 
of head and neck squamous cell carcinoma by the 
Interferon-inducible gene IFI16. Cancer Lett 
2010;287:33–43. 
28. Piccaluga PP, Califano A, Klein U, Agostinelli C, Bellosillo 
B, Gimeno E, et al. Gene expression analysis 
provides a potential rationale for revising the histological 
grading of follicular lymphomas. Haematologica 
2008;93:1033–8. 
29. Piccaluga PP, De Falco G, Kustagi M, Gazzola A, 
Agostinelli C, Tripodo C, et al. Gene expression analysis 
uncovers similarity and differences among Burkitt 
lymphoma subtypes. Blood 2011;117:3596–608. 
30. Zanotti R, Ambrosetti A, Lestani M, Ghia P, Pattaro 
C, Remo A, et al. ZAP-70 expression, as detected by 
immunohistochemistry on bone marrow biopsies from 
early-phase CLL patients, is a strong adverse prognostic 
factor. Leukemia 2007;21:102–9. 
31. Piccaluga PP, Agostinelli C, Califano A, Carbone A, 
Fantoni L, Ferrari S, et al. Gene expression analysis 
of angioimmunoblastic lymphoma indicates derivation 
from T follicular helper cells and vascular endothelial 
growth factor deregulation. Cancer Res 2007;67: 
10703–10. 
32. Piccaluga PP, Agostinelli C, Califano A, Rossi M, 
Basso K, Zupo S, et al. Gene expression analysis of 
peripheral T cell lymphoma, unspecified, reveals 
distinct profiles and new potential therapeutic targets. 
J Clin Invest 2007;117:823–34. 
33. Purroy N, Abrisqueta P, Carabia J, Carpio C, Palacio 
C, Bosch F, et al. Co-culture of primary CLL cells 
with bone marrow mesenchymal cells, CD40 ligand 
and CpG ODN promotes proliferation of chemoresistant 
CLL cells phenotypically comparable to those 
proliferating in vivo. Oncotarget 2015;6:7632–43. 
34. Billot K, Soeur J, Chereau F, Arrouss I, Merle-B_eral 
H, Huang ME, et al. Deregulation of Aiolos expression 
in chronic lymphocytic leukemia is associated 
with epigenetic modifications. Blood 2011;117:1917– 
27. 
35. Fo_a R, Del Giudice I, Guarini A, Rossi D, Gaidano 
G. Clinical implications of the molecular genetics of 
chronic lymphocytic leukemia. Haematologica 2013; 
98:675–85. 
36. Gazzola A, Broccoli A, Stefoni V. Stem Cell Transplantation 
in Chronic Lymphocytic Leukemia, Innovations 
in Stem Cell Transplantation. Rijeka, Croatia: 
InTech, 2013. 
37. Nabhan C, Rosen ST. Chronic lymphocytic leukemia: 
a clinical review. JAMA 2014;312:2265–76. 
38. G€obel M, Eisele L, M€ollmann M, H€uttmann A, 
Johansson P, Scholtysik R, et al. Progranulin is a 
novel independent predictor of disease progression 
and overall survival in chronic lymphocytic leukemia. 
PLoS ONE 2013;8:e72107. 
39. Mondini M, Costa S, Sponza S, Gugliesi F, Gariglio 
M, Landolfo S. The interferon-inducible HIN-200 
gene family in apoptosis and inflammation: implication 
for autoimmunity. Autoimmunity 2010;43:226– 
31. 
40. Dawson MJ, Elwood NJ, Johnstone RW, Trapani JA. 
The IFN-inducible nucleoprotein IFI-16 is expressed 
in cells of the monocyte lineage, but is rapidly and 
markedly down-regulated in other myeloid precursor 
populations. J Leukoc Biol 1998;64:546–54. 
41. Wei W, Clarke CJ, Somers GR, Cresswell KS, Loveland 
KA, Trapani JA, et al. Expression of IFI 16 in 
epithelial cells and lymphoid tissues. Histochem Cell 
Biol 2003;119:45–54. 
Table 1 
 
 
Fig. 1. IFI16 protein expression. IFI16 expression in CLL lymph node biopsies: examples of 
cases with low expression 
(partial expression below cut-off of 50% of the cells; 
examples of weak positive cells are highlighted by black 
arrows) (A) and high expression (B). 
 
Table 2. Correlation between protein IFI16 expression 
and the main clinico-pathological parameters 
Parameter Test p-value for possible 
correlation 
 
 
 
  
Fig. 2. Differential expression of IFI16 protein in cases 
carrying or not 13q abnormalities as detected by FISH 
analysis. Two-tailed T-test was used for comparison. 
Table 3 
 
 Fig. 3. Kaplan–Meier plots of CLL patients according to risk factors significantly associated 
with overall survival. The 
outcome according to chromosome 14 abnormalities (A), chromosome 17 abnormalities 
(B), and IFI16 protein expression 
(C) are shown. In panel D, four groups were designated based on the expression of IFI16, 
CD38, and ZAP70 (Group 1: 
IFI16+ and ZAP70/CD38-; Group 2: IFI16+ and ZAP70/CD38+; Group 3: IFI16- and 
ZAP70/CD38+; Group 4: IFI16- 
and ZAP70/CD38-). 
Table 4 
  
 
 
 
Fig. 4. Gene expression analysis of CLL according to IFI16 expression. Supervised 
analysis was performed in CLL cases 
with high vs low IFI16 gene expression. Based on the expression of 226 genes 
(corresponding to 271 probe sets), cases with 
higher or lower IFI16 levels were clearly discriminated (A). The dendrograms are 
generated using a hierarchical clustering 
algorithm based on the average-linkage method. In the matrix, each column represents a 
sample and each row represents a 
gene. The color scale bar shows the relative gene expression changes normalized by the 
standard deviation (0 is the mean 
expression level of a given gene). The above-mentioned 271 genes turned out to be 
significantly enriched in relevant oncogenic 
pathways (B) and GeneOntology Biological Processes (C). 
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